Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Enzon Commences Phase II Trial Of PEG-SN38
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer.

FDA Advisory Panel Recommends Approval Of The SEDASYS(R) System
Ethicon Endo-Surgery today announced that the Anesthesiology and Respiratory Therapy Devices Advisory Committee of the U.S. Food and Drug Administration (FDA) voted in favor of approval of the SEDASYS(R) System for use by physician/nurse teams to administer minimal-to-moderate propofol sedation during screening and diagnostic procedures for colorectal cancer (colonoscopy) and the upper gastrointestinal tract (EGD). The SEDASYS(R) System, the first computer-assisted personalized sedation (CAPS) system, integrates drug delivery and patient monitoring to enable propofol sedation personalized to each patient"s needs.
News of the day
AARP Responds To Health Reform Scare Tactics
AARP Executive Vice President John Rother issued the following statement in response to recent commentary by Betsy McCaughey in various media outlets on health care reform measures passed or currently being considered by Congress.
Endocrinology

Radiotherapy Link To Breast Cancer And Heart Disease Found

Scientists have found a way to identify breast cancer patients at risk of heart disease after radiotherapy, according to a report published yesterday. Radiotherapy is commonly used to treat those patients who have had breast conservation surgery, and those who are at high risk of the cancer returning after mastectomy. When the breast tumour is on the left side, a small part of the heart is within the treatment range which can lead to heart disease. Dr Paul Symonds, of the University of Leicester"s Department of Cancer Studies and Molecular Medicine, studied 149 patients who had undergone radiotherapy for breast cancer. After treatment some patients developed red dilated blood vessels (telangiectasia) on the breast or chest wall, previously thought to be unsightly rather than of any medical significance. The findings, published in the British Journal of Cancer, revealed that only those who had radiotherapy on the left side developed heart problems, which occurred between three and 12 years after treatment. Over half of those who developed heart problems showed signs of telangiectasia. These figures are significant enough to suggest that telangiectasia could be a marker to predict the risk of heart disease after radiotherapy for breast cancer on the left side. Dr Symonds is now studying the genes of 1,000 patients who have undergone radiotherapy to try and identify those likely to experience side effects which could lead to heart disease. He said, "Ultimately this research could lead to a test to predict which patients will develop severe radiotherapy side-effects. Clinicians can then use this information to advise patients of their risk before treatment and help the radiotherapist give the most appropriate treatment." Pamela Goldberg, Chief Executive, Breast Cancer Campaign, which funded the study said, "More and more women are living with breast cancer as a long term manageable condition rather than an incurable disease. It is therefore vital that treatment not only improves the chance of survival but does not lead to other negative health consequences and maintains a good quality of life." Breast Cancer Campaign


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009